REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Chen CL, Fan ST, Lee SG, Makuuchi M, Tanaka K. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation 2003;75:S6-11.
3. Yoon YI, Lee SG. Living donor liver transplantation for hepatocellular carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000.
4. Hong G, Yi NJ, Suh SW, et al. Preoperative selective desensitization of liver donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volume. J Korean Med Sci 2014;29:640-7.
5. Egawa H. Challenge to ABO blood type barrier in living donor liver transplantation. Hepatobiliary Pancreatic Dis Int 2020;19:342-8.
6. Wesson RN, Etchill EW, Garonzik-Wang J. Application and interpretation of histocompatibility data in liver transplantation. Curr Opin Organ Transplant 2017;22:499-504.
7. Egawa H, Teramukai S, Haga H, et al. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study. Am J Transplant 2014;14:102-14.
8. Kim SH, Lee EC, Na BG, Park SJ. Impact of ABO-incompatibility on hepatocellular carcinoma recurrence after living donor liver transplantation. Eur J Surg Oncol 2019;45:180-6.
9. Kim JM, Kwon CHD, Joh JW, et al. ABO-incompatible living donor liver transplantation with rituximab and total plasma exchange does not increase hepatocellular carcinoma recurrence. Transplantation 2018;102:1695-701.
10. Yoon YI, Song GW, Lee SG, et al. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma. J Hepatol 2018;68:1153-62.
11. Kamo N, Kaido T, Hammad A, et al. Impact of elderly donors for liver transplantation: a single-center experience. Liver transpl 2015;21:591-8.
12. Kamo N, Kaido T, Hamaguchi Y, et al. Impact of enteral Nutrition with an immunomodulating diet enriched with hydrolyzed whey peptide on infection after liver transplantation. World J Surg 2018;42:3715-25.
13. Ueda Y, Uemoto S. Interferon-free therapy for hepatitis C in liver transplantation recipients. Transplantation 2016;100:54-60.
14. Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res 2013;43:67-71.
15. Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK 506 in pediatric living related liver transplantation. Transplantation 1996;61:247-52.
16. Takada Y, Ueda M, Ito T, et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006;12:912-9.
17. Fukumitsu K, Hammad A, Kaido T, et al. Validation of steroid-free immunosuppression regimen after liver transplantation. J Clin Gastroensterol Treat 2015;1:1-4.
18. Egawa H, Umeshita K, Uemoto S. Optimal dosage regimen for rituximab in ABO-incompatible living donor liver transplantation. J Hepatobiliary Pancreat Sci 2017;24:89-94.
19. Takada Y, Ito T, Ueda M, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis 2007;25:299-302.
20. Egawa H, Shimamura T, Todo S. Impact of desensitization for ABO-blood bar- rier on living donor liver transplantation for hepatocellular carcinoma. Nihon Shokakibyo Gakkai Zasshi 2014;111:892-8.
21. Olnes MJ, Kotliarov Y, Biancotto A, et al. Effects of systemically administered hydrocortisone on the human immunome. Sci Rep 2016;14:23002.
22. Unitt E, Marshall A, Gelson W, et al. Tumor lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006;45:246-253.
23. Lee JY, Kim YH, Yi NJ, et al. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Cli Mol Hepatol 2014;20:192-203.
24. Wu LW, Tai Q, Zhu XF, He XS. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center. J Dig Dis 2013;14:38-44.
